elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Everolimus
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Everolimus
RIS
0.000
(Research Intensity Score)
Papers
54
Top papers
Gastroenteropancreatic Neuroendocrine Tumors
2018 · 614 citations
Pheochromocytomas and Paragangliomas—Current Management
2025 · 15 citations
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
2025 · 9 citations
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial
2025 · 4 citations
Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients
2024 · 18 citations
Tumor fat composition predicts response to everolimus and supports low-dose therapy in TSC-associated renal angiomyolipomas: a multicenter prospective study
2026
Preclinical Evaluation of a 177 Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus
2025 · 3 citations
Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis
2022 · 35 citations
Lower hepatitis E clearance rates in thoracic organ recipients compared to visceral organ recipients: an effect of stronger immunosuppression?
2026
Newest papers
Tumor fat composition predicts response to everolimus and supports low-dose therapy in TSC-associated renal angiomyolipomas: a multicenter prospective study
2026
Lower hepatitis E clearance rates in thoracic organ recipients compared to visceral organ recipients: an effect of stronger immunosuppression?
2026
A case report of acute carcinoid heart failure during lutetium-177 dotatate–triapine treatment for well-differentiated neuroendocrine tumors
2026
Alliance A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor-Positive Bronchial Neuroendocrine Tumors
2026
Preclinical Evaluation of a 177Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus.
2026
Pheochromocytomas and Paragangliomas—Current Management
2025 · 15 citations
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
2025 · 9 citations
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial
2025 · 4 citations
Preclinical Evaluation of a 177 Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus
2025 · 3 citations
Browse all papers →
Everolimus's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Everolimus's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link